Mechanism of action
Pregabalin binds with high affinity to the α2δ (alpha-2-delta) subunit of presynaptic voltage-gated calcium channels in the central nervous system. This binding reduces calcium influx at nerve terminals, which in turn decreases the release of excitatory neurotransmitters including glutamate, norepinephrine, substance P, and calcitonin gene-related peptide.
Despite its structural similarity to GABA (gamma-aminobutyric acid), pregabalin does not bind to GABA receptors, does not convert to GABA or another GABA receptor agonist, and does not directly modulate GABA transport or metabolism. The reduction in excitatory neurotransmitter release leads to decreased neuronal excitability, which underlies its anticonvulsant, analgesic, and anxiolytic properties.
The therapeutic effect develops over several days as the drug modulates synaptic transmission in hyperexcitable neurons, particularly in dorsal horn neurons involved in pain transmission and in cortical neurons involved in seizure generation.
- Pregabalin binds α2δ subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release; does NOT bind GABA receptors
- Schedule V controlled substance with abuse potential; monitor for misuse, especially in patients with substance use history
- Requires dose adjustment in renal impairment; nearly 100% renally excreted unchanged
- Common adverse effects: dizziness, somnolence, weight gain, peripheral edema (all dose-dependent)
- Black box warning for increased suicidal ideation (applies to all antiepileptic drugs)
- Must taper gradually to discontinue; abrupt cessation may cause withdrawal symptoms and rebound seizures
- Risk of angioedema, especially when combined with ACE inhibitors
- FDA-approved for diabetic neuropathy, postherpetic neuralgia, fibromyalgia, and adjunctive therapy for partial seizures
Indications
Pregabalin is FDA-approved for several conditions:
Neuropathic pain
- Diabetic peripheral neuropathy: First-line treatment for painful diabetic neuropathy
- Postherpetic neuralgia: Effective for pain following herpes zoster
- Spinal cord injury-associated neuropathic pain
Fibromyalgia
Pregabalin was the first FDA-approved medication specifically for fibromyalgia management, reducing widespread pain and improving function.
Epilepsy
Adjunctive therapy for partial-onset seizures in adults. It is not used as monotherapy for seizures.
Off-label uses
- Generalized anxiety disorder (approved in Europe, not in the US)
- Chronic pain conditions
- Restless legs syndrome
- Social anxiety disorder
- Withdrawal symptoms from alcohol and benzodiazepines
Pharmacokinetics
Absorption: Pregabalin is rapidly absorbed with oral bioavailability greater than 90% across the dose range. Food slightly decreases the rate but not the extent of absorption. Peak plasma concentrations occur within 1.5 hours when taken on an empty stomach.
Distribution: Pregabalin does not bind to plasma proteins and has a volume of distribution of approximately 0.5 L/kg. It readily crosses the blood-brain barrier via the L-amino acid transport system.
Metabolism: Pregabalin undergoes negligible metabolism in humans. Approximately 98% of the drug is excreted unchanged in urine. The small amount that is metabolized yields N-methylpregabalin.
Elimination: Renal excretion is the primary route of elimination, with a half-life of approximately 6 hours in patients with normal renal function. Dose adjustment is required in renal impairment based on creatinine clearance. The drug is effectively removed by hemodialysis, and supplemental doses are needed post-dialysis.
Steady state is achieved within 24 to 48 hours with regular dosing. The predictable pharmacokinetics and lack of drug metabolism make pregabalin less susceptible to drug-drug interactions compared to many other anticonvulsants.
Adverse effects
Most common adverse effects
- Dizziness and somnolence: Occur in 20-30% of patients; dose-dependent
- Weight gain: Dose-dependent; average 2-3 kg over 12 weeks
- Peripheral edema: Occurs in 5-10% of patients
- Dry mouth
- Blurred vision and diplopia
- Difficulty with concentration and attention
- Ataxia and tremor
Serious adverse effects
- Angioedema: Rare but potentially life-threatening; presents with facial, oral, or laryngeal swelling
- Hypersensitivity reactions: Including rash, dyspnea, and wheezing
- Increased suicidal ideation: Black box warning for all antiepileptic drugs; monitor for emergence of depression or suicidal thoughts
- Rhabdomyolysis: Rare cases reported, particularly with concurrent medications
- Severe dermatologic reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis reported rarely
- PR interval prolongation: Usually clinically insignificant but caution in heart block
Other notable effects
- Euphoria and abuse potential: Schedule V controlled substance in the US
- Cognitive impairment: "Brain fog," memory problems
- Decreased platelet count: Usually mild
- Elevated creatine kinase: Monitor if muscle pain or weakness develops
- Withdrawal symptoms: Taper gradually to avoid insomnia, nausea, headache, anxiety, and seizures (if used for epilepsy)
Contraindications and warnings
Absolute contraindications
- Known hypersensitivity to pregabalin or any component of the formulation
Warnings and precautions
Renal impairment: Dose adjustment is mandatory based on creatinine clearance. Accumulation occurs with reduced renal function, increasing risk of adverse effects.
Abrupt discontinuation: Taper gradually over at least one week to minimize withdrawal symptoms. Sudden cessation in patients with seizure disorders may precipitate seizure activity or increase seizure frequency.
Pregnancy and lactation: Pregnancy category C. Animal studies showed developmental toxicity. Use only if benefit outweighs risk. Pregabalin is excreted in breast milk; consider risks and benefits before breastfeeding.
Angioedema: Discontinue immediately if angioedema occurs. Higher risk in patients taking ACE inhibitors concurrently.
Ophthalmologic effects: Inform patients to report vision changes. Ophthalmologic monitoring may be considered in patients with pre-existing eye disease.
Decreased platelet count and PR prolongation: Use caution in patients with bleeding disorders or heart block.
Tumorigenic potential: Animal studies showed increased incidence of hemangiosarcoma. Clinical significance unknown; no increased cancer risk demonstrated in humans.
Abuse potential: Schedule V controlled substance. Risk is higher in patients with history of substance abuse. Monitor for signs of misuse or abuse.
Driving and operating machinery: May impair mental and physical abilities. Warn patients about drowsiness and dizziness, especially when initiating therapy or increasing dose.
Drug interactions
Pregabalin has relatively few drug interactions due to minimal protein binding and negligible hepatic metabolism.
Pharmacodynamic interactions
CNS depressants: Additive sedative effects when combined with:
- Opioids (increased risk of respiratory depression)
- Benzodiazepines
- Alcohol
- First-generation antihistamines
- Other sedating medications
Monitor patients closely and consider dose reduction of one or both agents.
ACE inhibitors: Increased risk of angioedema when pregabalin is combined with ACE inhibitors (e.g., lisinopril, enalapril). The mechanism is not fully understood but may involve additive effects on bradykinin pathways.
Thiazolidinediones: Concurrent use with rosiglitazone or pioglitazone may potentiate weight gain and peripheral edema. Monitor fluid status, especially in patients with heart failure.
Pharmacokinetic interactions
Pregabalin exhibits minimal pharmacokinetic interactions. It does not induce or inhibit cytochrome P450 enzymes and does not affect the pharmacokinetics of most other drugs.
No dose adjustment needed when pregabalin is used with:
- Oral contraceptives
- Phenytoin
- Carbamazepine
- Valproic acid
- Lamotrigine
- Warfarin
- Digoxin
Renal excretion: Since both pregabalin and gabapentin are renally excreted, no significant interaction occurs between them, though therapeutic duplication should be avoided.
Clinical pearls
- Pregabalin vs gabapentin: Pregabalin has more predictable pharmacokinetics with linear absorption (gabapentin has dose-dependent, saturable absorption), allowing for simpler twice-daily dosing and more consistent plasma levels.
- Weight gain is dose-dependent: Occurs in approximately 10-15% of patients. Counsel patients at initiation and monitor weight regularly, especially in diabetic patients where weight gain may worsen glycemic control.
- Rapid onset of action: Analgesic effects may be observed within one week, faster than many other neuropathic pain medications (e.g., tricyclic antidepressants, SNRIs).
- Renal dosing is essential: Pregabalin is almost entirely renally eliminated. Failure to adjust dose in renal impairment leads to accumulation and increased adverse effects, particularly sedation and confusion in elderly patients.
- Schedule V controlled substance: Has abuse potential, particularly in patients with history of substance use disorders. Reports of recreational use for euphoric effects, especially at high doses.
- Taper to discontinue: To avoid withdrawal symptoms (insomnia, nausea, headache, diarrhea) and rebound seizures in epilepsy patients, taper over at least one week. Longer tapers may be needed for patients on high doses or long-term therapy.
- Check for angioedema early: Most cases occur within the first weeks of therapy. Educate patients to recognize facial swelling and seek immediate medical attention.
- Not first-line for anxiety in the US: While effective for generalized anxiety disorder and approved in Europe, pregabalin is not FDA-approved for anxiety in the United States. Use is off-label.
- May improve sleep quality: Many patients report improved sleep, which can be beneficial in fibromyalgia and chronic pain conditions but may contribute to daytime somnolence.
- Limited drug interactions: Makes it a good choice in polypharmacy situations, particularly in elderly patients on multiple medications, though CNS depression remains a concern.
PREGAB for adverse effects: Peripheral edema, Respiratory depression (with CNS depressants), Euphoria/abuse, Gain weight, Angioedema, Blurred vision
Practice questions
1. A 58-year-old man with type 2 diabetes mellitus presents with burning pain in both feet for the past 6 months. He describes the pain as constant, worse at night, and rates it 7/10. Physical examination reveals decreased sensation to light touch and vibration in both feet. HbA1c is 8.2%. He is started on pregabalin. Four weeks later, he returns reporting improved pain but now has swelling in both ankles. Which of the following is the most likely explanation for his new symptom?
2. A 45-year-old woman with fibromyalgia has been taking pregabalin 150 mg twice daily for 8 months with good pain control. She presents to the emergency department 3 days after abruptly stopping the medication due to insurance issues. She complains of severe insomnia, nausea, headache, and increased anxiety. Vital signs are: temperature 37.2°C, pulse 98/min, BP 142/88 mmHg. Physical examination is unremarkable. Which of the following best explains her current presentation?
3. A 72-year-old man with postherpetic neuralgia is started on pregabalin for pain management. His medical history includes hypertension treated with lisinopril, stage 3 chronic kidney disease (eGFR 45 mL/min/1.73 m²), and coronary artery disease. Three days after starting pregabalin, he develops facial swelling and difficulty swallowing. On examination, there is marked periorbital and lip swelling without urticaria. Which of the following best explains this patient's presentation?
Frequently asked questions
How does pregabalin work?
Pregabalin binds to the α2δ subunit of voltage-gated calcium channels in the central nervous system, reducing calcium influx and decreasing the release of excitatory neurotransmitters like glutamate and substance P. Despite being structurally similar to GABA, it does not bind to GABA receptors or affect GABA metabolism. This mechanism reduces neuronal excitability, providing anticonvulsant and analgesic effects, particularly in hyperexcitable pain and seizure pathways.
What are the side effects of pregabalin?
The most common side effects are dizziness and somnolence (20-30%), weight gain (average 2-3 kg), peripheral edema, dry mouth, and blurred vision. Serious but rare adverse effects include angioedema, hypersensitivity reactions, increased suicidal ideation (black box warning), rhabdomyolysis, and severe skin reactions. Cognitive impairment and difficulty concentrating are also reported. The drug has abuse potential and is classified as Schedule V controlled substance.
Is pregabalin a controlled substance?
Yes, pregabalin is classified as a Schedule V controlled substance in the United States due to its abuse and dependence potential. Patients may misuse it for euphoric effects, especially at higher doses. The risk is elevated in individuals with a history of substance use disorders. While Schedule V represents the lowest potential for abuse among controlled substances, prescribers should still monitor for signs of misuse and document appropriate medical necessity.
What is the difference between pregabalin and gabapentin?
Both are gabapentinoids that bind α2δ subunits of calcium channels, but pregabalin has more predictable, linear pharmacokinetics with greater than 90% bioavailability at all doses, while gabapentin has dose-dependent, saturable absorption. Pregabalin allows simpler twice-daily dosing and achieves more consistent plasma levels. Pregabalin is a controlled substance (Schedule V) while gabapentin is not federally controlled (though some states regulate it). Pregabalin is FDA-approved for fibromyalgia, whereas gabapentin is not, though both are used for neuropathic pain.
Can pregabalin be stopped suddenly?
No, pregabalin should not be stopped abruptly. It must be tapered gradually over at least one week to minimize withdrawal symptoms including insomnia, nausea, headache, anxiety, diarrhea, and flu-like symptoms. In patients taking pregabalin for seizure disorders, sudden discontinuation may precipitate increased seizure frequency or status epilepticus. Longer tapers may be necessary for patients on high doses or those who have been on the medication for extended periods.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N02BF02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.